Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of chronic obstructive pulmonary disease~2. Relatively stable airway obstruction with a post-bronchodilator 30% \</= Forced Expiratory Volume in 1 second (FEV1)\<80% of predicted normal and a post-bronchodilator FEV1/(Forced Vital Capacity)FVC \<70%~3. Male or female patients, 40 years of age or older~4. Smoking history of more than 10 pack years~5. Ability to perform technically acceptable pulmonary function tests and maintain records~6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler, Accuhaler and from a metered dose inhaler (MDI)~Exclusion criteria:~1. Significant disease other than COPD~2. COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or iv) or hospitalization in the last 3 months.~3. Clinically relevant abnormal lab values~4. History of asthma~5. Diagnosis of thyrotoxicosis~6. Diagnosis of paroxysmal tachycardia~7. History of myocardial infarction~8. Unstable or life-threatening cardiac arrhythmia~9. Hospitalization for heart failure within the past year~10. Known active tuberculosis~11. malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years~12. History of life-threatening pulmonary obstruction~13. History of cystic fibrosis~14. Clinically evident bronchiectasis~15. History of significant alcohol or drug abuse~16. History of thoracotomy with pulmonary resection~17. oral or patch ß-adrenergics~18. Oral corticosteroid medication within 6 weeks prior to Visit 1~19. Regular use daytime oxygen therapy for more than one hour per day~20. Pulmonary rehabilitation program in the six weeks prior to the screening visit~21. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit~22. Known hypersensitivity to ß-adrenergic drugs, BAC, EDTA~23. Pregnant or nursing women

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T+O FDC dosage 1 (Type: EXPERIMENTAL): Low dose
- T+O FDC dosage 2 (Type: EXPERIMENTAL): High dose
- ICS/LABA FDC Dosage 1 (Type: ACTIVE_COMPARATOR): Low dose
- ICS/LABA FDC Dosage 2 (Type: ACTIVE_COMPARATOR): High dose

Based on this trial design, predict the completion outcome and termination type (if applicable).